Cost-Effectiveness Analysis of Screening Chronic Kidney Disease in Iran

Introduction: The prevalence of Chronic Kidney Disease (CKD) in Iran amounts to 15.14%, which is higher than the global average. Given the substantial cost of this disease, health insurance companies need evidence of the cost-effectiveness of screening for the disease in adults at risk so that they...

Full description

Bibliographic Details
Main Authors: Hamid Ravaghi, Ali Farzaneh, Mehdi Ebrahimnia, Zohreh Rostami, Mohammad Hasan Hashemi madani
Format: Article
Language:English
Published: JCDR Research and Publications Private Limited 2019-11-01
Series:Journal of Clinical and Diagnostic Research
Subjects:
Online Access:https://jcdr.net/articles/PDF/13295/42446_CE[Ra1]_F(KM)_PF1(AG_SHU)_PFA(SHU)_PB(AG_SHU)_PN(SL).pdf
id doaj-b5bd52b71b9143d2bb47bf94fbdca441
record_format Article
spelling doaj-b5bd52b71b9143d2bb47bf94fbdca4412020-11-25T02:42:09ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2019-11-011311IC01IC0410.7860/JCDR/2019/42446.13295Cost-Effectiveness Analysis of Screening Chronic Kidney Disease in IranHamid Ravaghi0Ali Farzaneh1Mehdi Ebrahimnia2Zohreh Rostami3Mohammad Hasan Hashemi madani4Associate Professor, Department of Health Care Services Management, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.Postgraduate Student, Department of Health Care Services Management, School of Health Management and Information Sciences, International Campus, Iran University of Medical Sciences, Tehran, Iran.Assistant Professor, Health Management Research Centre, Baqiyatallah University of Medical Sciences, Tehran, Iran.Associate Professor, Nephrology and Urology Research Centre, Baqiyatallah University of Medical Science, Tehran, Iran.Health Management Research Centre, Baqiyatallah University of Medical Sciences, Tehran, Iran.Introduction: The prevalence of Chronic Kidney Disease (CKD) in Iran amounts to 15.14%, which is higher than the global average. Given the substantial cost of this disease, health insurance companies need evidence of the cost-effectiveness of screening for the disease in adults at risk so that they can control the prevalence of the disease and the associated incremental medical costs by implementing a nationwide screening. Aim: To explore the cost-effectiveness of screening for CKD among adults as compared with having a non-intervention strategy. Materials and Methods: The study had a cross-sectional design and uses the cost-effectiveness analysis approach to compare the costs and outcomes of screening versus nonscreening CKD. The estimated Glomerular Filtration Rate (GFR) was used for primary screening of the population. For this purpose, blood creatinine was measured; subsequently, urine creatinine and volume were analysed. However, some complementary measures and diagnostic tests were employed for positive cases, including the kidney ultrasonography. Costs and outcomes of the two strategies was calculated using a Markov decision model. This model is designed based on the natural course of CKD and GFR as a five-stage model. Costs of services required for patients were calculated based on Iran Health Insurance Organisation database, and outcome data were extracted in terms of the Quality-Adjusted Life-Year (QALY) index. Using TreeAge software, costs and outcomes were simulated for 1000 patients, and sensitivity analysis was used to test the reliability of the model data. Results: For an adult population, the cost-effectiveness ratio for screening versus non-screening was 277,686,954 Rials per QALY, which was the effective cost. The results of one-way sensitivity analysis on the variables of the model shows that the screening strategy can be considered a dominant strategy in different domains. Conclusion: Given the high prevalence of CKD in Iran, early detection of this disease via adult population screening is cost-effective for health insurance companies, and these organisations can control the costs of dialysis and kidney transplantation by reducing the rate of patient transitions from early to the final stages of the disease.https://jcdr.net/articles/PDF/13295/42446_CE[Ra1]_F(KM)_PF1(AG_SHU)_PFA(SHU)_PB(AG_SHU)_PN(SL).pdfinsuranceqaly indexmass screening
collection DOAJ
language English
format Article
sources DOAJ
author Hamid Ravaghi
Ali Farzaneh
Mehdi Ebrahimnia
Zohreh Rostami
Mohammad Hasan Hashemi madani
spellingShingle Hamid Ravaghi
Ali Farzaneh
Mehdi Ebrahimnia
Zohreh Rostami
Mohammad Hasan Hashemi madani
Cost-Effectiveness Analysis of Screening Chronic Kidney Disease in Iran
Journal of Clinical and Diagnostic Research
insurance
qaly index
mass screening
author_facet Hamid Ravaghi
Ali Farzaneh
Mehdi Ebrahimnia
Zohreh Rostami
Mohammad Hasan Hashemi madani
author_sort Hamid Ravaghi
title Cost-Effectiveness Analysis of Screening Chronic Kidney Disease in Iran
title_short Cost-Effectiveness Analysis of Screening Chronic Kidney Disease in Iran
title_full Cost-Effectiveness Analysis of Screening Chronic Kidney Disease in Iran
title_fullStr Cost-Effectiveness Analysis of Screening Chronic Kidney Disease in Iran
title_full_unstemmed Cost-Effectiveness Analysis of Screening Chronic Kidney Disease in Iran
title_sort cost-effectiveness analysis of screening chronic kidney disease in iran
publisher JCDR Research and Publications Private Limited
series Journal of Clinical and Diagnostic Research
issn 2249-782X
0973-709X
publishDate 2019-11-01
description Introduction: The prevalence of Chronic Kidney Disease (CKD) in Iran amounts to 15.14%, which is higher than the global average. Given the substantial cost of this disease, health insurance companies need evidence of the cost-effectiveness of screening for the disease in adults at risk so that they can control the prevalence of the disease and the associated incremental medical costs by implementing a nationwide screening. Aim: To explore the cost-effectiveness of screening for CKD among adults as compared with having a non-intervention strategy. Materials and Methods: The study had a cross-sectional design and uses the cost-effectiveness analysis approach to compare the costs and outcomes of screening versus nonscreening CKD. The estimated Glomerular Filtration Rate (GFR) was used for primary screening of the population. For this purpose, blood creatinine was measured; subsequently, urine creatinine and volume were analysed. However, some complementary measures and diagnostic tests were employed for positive cases, including the kidney ultrasonography. Costs and outcomes of the two strategies was calculated using a Markov decision model. This model is designed based on the natural course of CKD and GFR as a five-stage model. Costs of services required for patients were calculated based on Iran Health Insurance Organisation database, and outcome data were extracted in terms of the Quality-Adjusted Life-Year (QALY) index. Using TreeAge software, costs and outcomes were simulated for 1000 patients, and sensitivity analysis was used to test the reliability of the model data. Results: For an adult population, the cost-effectiveness ratio for screening versus non-screening was 277,686,954 Rials per QALY, which was the effective cost. The results of one-way sensitivity analysis on the variables of the model shows that the screening strategy can be considered a dominant strategy in different domains. Conclusion: Given the high prevalence of CKD in Iran, early detection of this disease via adult population screening is cost-effective for health insurance companies, and these organisations can control the costs of dialysis and kidney transplantation by reducing the rate of patient transitions from early to the final stages of the disease.
topic insurance
qaly index
mass screening
url https://jcdr.net/articles/PDF/13295/42446_CE[Ra1]_F(KM)_PF1(AG_SHU)_PFA(SHU)_PB(AG_SHU)_PN(SL).pdf
work_keys_str_mv AT hamidravaghi costeffectivenessanalysisofscreeningchronickidneydiseaseiniran
AT alifarzaneh costeffectivenessanalysisofscreeningchronickidneydiseaseiniran
AT mehdiebrahimnia costeffectivenessanalysisofscreeningchronickidneydiseaseiniran
AT zohrehrostami costeffectivenessanalysisofscreeningchronickidneydiseaseiniran
AT mohammadhasanhashemimadani costeffectivenessanalysisofscreeningchronickidneydiseaseiniran
_version_ 1724775024974364672